Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals

Journal of Viral Hepatitis

Volumn 22, Issue 12, 2015, Pages 983-991

  Burchill, M A ^a   Golden Mason, L ^a   Wind Rotolo, M ^b   Rosen, H R ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

direct acting antiviral (DAA); HCV; NK cells; T cells; T cell immunoreceptor with Ig and ITIM domains

Indexed keywords

ASUNAPREVIR PLUS BECLABUVIR PLUS DACLATASVIR; CELL PROTEIN; T CELL IMMUNORECEPTOR WITH IG AND ITIM DOMAIN; UNCLASSIFIED DRUG; 8-CYCLOHEXYL-N-((DIMETHYLAMINO)SULFONYL)-1,1A,2,12B-TETRAHYDRO-11-METHOXY-1A-((3-METHYL-3,8-DIAZABICYCLO(3.2.1)OCT-8-YL)CARBONYL)CYCLOPROP(D)INDOLO(2,1-A)(2)BENZAZEPINE-5-CARBOXAMIDE; ANTIVIRUS AGENT; ASUNAPREVIR; BENZAZEPINE DERIVATIVE; BMS-790052; CD3 ANTIGEN; IMIDAZOLE DERIVATIVE; IMMUNOGLOBULIN RECEPTOR; INDOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; SULFONAMIDE; TIGIT PROTEIN, HUMAN;

ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC HEPATITIS C; CLINICAL ARTICLE; COHORT ANALYSIS; HUMAN; HUMAN CELL; IMMUNOREGULATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE SUBPOPULATION; MEMORY T LYMPHOCYTE; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRAL CLEARANCE; BIOSYNTHESIS; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; VIRUS LOAD;

ANTIGENS, CD3; ANTIVIRAL AGENTS; BENZAZEPINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; IMMUNOLOGIC MEMORY; INDOLES; ISOQUINOLINES; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; RECEPTORS, IMMUNOLOGIC; SULFONAMIDES; VIRAL LOAD;

EID: 84973382897     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12465     Document Type: Article

References (42)

1. Rosen HR,. Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest 2013; 123 (10): 4121-4130.
2. Virgin HW, Wherry EJ, Ahmed R,. Redefining chronic viral infection. Cell 2009; 138 (1): 30-50.
3. Golden-Mason L, Palmer B, Klarquist J, Mengshol JA, Castelblanco N, Rosen HR,. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8 + T cells associated with reversible immune dysfunction. J Virol 2007; 81 (17): 9249-9258.
4. Golden-Mason L, Palmer BE, Kassam N, et al,. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4 + and CD8 + T cells. J Virol 2009; 83 (18): 9122-9130.
5. Radziewicz H, Ibegbu CC, Fernandez ML, et al,. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 2007; 81 (6): 2545-2553.
6. Bengsch B, Seigel B, Ruhl M, et al,. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8 + T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog 2010; 6 (6): e1000947.
7. Golden-Mason L, Klarquist J, Wahed AS, Rosen HR,. Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences. J Immunol 2008a; 180 (6): 3637-3641.
8. Seigel B, Bengsch B, Lohmann V, Bartenschlager R, Blum HE, Thimme R,. Factors that determine the antiviral efficacy of HCV-specific CD8(+) T cells ex vivo. Gastroenterology 2013; 144 (2): 426-436.
9. Yonkers NL, Sieg S, Rodriguez B, Anthony DD,. Reduced naive CD4 T cell numbers and impaired induction of CD27 in response to T cell receptor stimulation reflect a state of immune activation in chronic hepatitis C virus infection. J Infect Dis 2011; 203 (5): 635-645.
10. Lucas M, Vargas-Cuero AL, Lauer GM, et al,. Pervasive influence of hepatitis C virus on the phenotype of antiviral CD8 + T cells. J Immunol 2004; 172 (3): 1744-1753.
11. Moorman JP, Zhang CL, Ni L, et al,. Impaired hepatitis B vaccine responses during chronic hepatitis C infection: involvement of the PD-1 pathway in regulating CD4(+) T cell responses. Vaccine 2011; 29 (17): 3169-3176.
12. Kramer ES, Hofmann C, Smith PG, Shiffman ML, Sterling RK,. Response to hepatitis A and B vaccine alone or in combination in patients with chronic hepatitis C virus and advanced fibrosis. Dig Dis Sci 2009; 54 (9): 2016-2025.
13. Abdel-Hakeem MS, Bedard N, Badr G, et al,. Comparison of immune restoration in early versus late alpha interferon therapy against hepatitis C virus. J Virol 2010; 84 (19): 10429-10435.
14. Missale G, Pilli M, Zerbini A, et al,. Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection. Gut 2012; 61 (7): 1076-1084.
15. Barnes E, Gelderblom HC, Humphreys I, et al,. Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus infection. J Infect Dis 2009; 199 (6): 819-828.
16. Golden-Mason L, Rosen HR,. Natural killer cells: multifaceted players with key roles in hepatitis C immunity. Immunol Rev 2013; 255 (1): 68-81.
17. Morishima C, Paschal DM, Wang CC, et al,. Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology 2006; 43 (3): 573-580.
18. Bonorino P, Ramzan M, Camous X, et al,. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. J Hepatol 2009; 51 (3): 458-467.
19. Serti E, Chepa-Lotrea X, Kim YJ, et al,. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function. Gastroenterology 2015; 149 (1): 190-200. e2.
20. Mondelli MU,. Direct-acting antivirals cure innate immunity in chronic hepatitis C. Gastroenterology 2015; 149 (1): 25-28.
21. Kuniholm MH, Xie X, Anastos K, et al,. Association of chronic hepatitis C infection with T-cell phenotypes in HIV-negative and HIV-positive women. J Acquir Immune Defic Syndr 2014; 67 (3): 295-303.
22. Abdel-Hakeem MS, Bedard N, Murphy D, Bruneau J, Shoukry NH,. Signatures of protective memory immune responses during hepatitis C virus reinfection. Gastroenterology 2014; 147 (4): 870-881. e8.
23. Everson G, Cooper C, Hezode C, et al,. DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4. Liver Int 2015; 35 (1): 108-119.
24. Roederer M,. Interpretation of cellular proliferation data: avoid the panglossian. Cytometry A 2011; 79 (2): 95-101.
25. Everson GT, Sims KD, Rodriguez-Torres M, et al,. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014; 146 (2): 420-429.
26. Burgers WA, Riou C, Mlotshwa M, et al,. Association of HIV-specific and total CD8 + T memory phenotypes in subtype C HIV-1 infection with viral set point. J Immunol 2009; 182 (8): 4751-4761.
27. McMahan RH, Golden-Mason L, Nishimura MI, et al,. Tim-3 expression on PD-1 + HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest 2010; 120 (12): 4546-4557.
28. Kaech SM, Cui W,. Transcriptional control of effector and memory CD8 + T cell differentiation. Nat Rev Immunol 2012; 12 (11): 749-761.
29. Burton JR Jr, Klarquist J, Im K, et al,. Prospective analysis of effector and regulatory CD4 + T cells in chronic HCV patients undergoing combination antiviral therapy. J Hepatol 2008; 49 (3): 329-338.
30. Joller N, Hafler JP, Brynedal B, et al,. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol 2011; 186 (3): 1338-1342.
31. Bi J, Zhang Q, Liang D, et al,. T-cell Ig and ITIM domain regulates natural killer cell activation in murine acute viral hepatitis. Hepatology 2014a; 59 (5): 1715-1725.
32. Golden-Mason L, Madrigal-Estebas L, McGrath E, et al,. Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure. Gut 2008b; 57 (8): 1121-1128.
33. Golden-Mason L, Waasdorp Hurtado CE, Cheng L, Rosen HR,. Hepatitis C viral infection is associated with activated cytolytic natural killer cells expressing high levels of T cell immunoglobulin- and mucin-domain-containing molecule-3. Clin Immunol 2015; 158 (1): 114-125.
34. Gordon SM, Chaix J, Rupp LJ, et al,. The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity 2012; 36 (1): 55-67.
35. Grakoui A, Shoukry NH, Woollard DJ, et al,. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003; 302 (5645): 659-662.
36. Shoukry NH, Grakoui A, Houghton M, et al,. Memory CD8 + T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003; 197 (12): 1645-1655.
37. Smyk-Pearson S, Tester IA, Klarquist J, et al,. Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help. J Virol 2008; 82 (4): 1827-1837.
38. Johnston RJ, Comps-Agrar L, Hackney J, et al,. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 2014; 26 (6): 923-937.
39. Bi J, Zheng X, Chen Y, Wei H, Sun R, Tian Z,. TIGIT safeguards liver regeneration through regulating natural killer cell-hepatocyte crosstalk. Hepatology 2014b; 60 (4): 1389-1398.
40. Martin B, Hennecke N, Lohmann V, et al,. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. J Hepatol 2014; 61 (3): 538-543.
41. http://news.bms.com/press-release/rd-news/bristol-myers-squibb-statement-about-asunaprevir-us
42. Wiedmann M, Liebert UG, Oesen U, et al,. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology 2000; 31 (1): 230-234.